UNSPSC 51392414: Dopexamine dihydrochloride

This classification denotes a dopamine agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0VN909S60Y. European Medicines Agency schedules Dopexamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01819MIG. Dopexamine dihydrochloride generally arises in the molecular formula C22H32N2O2.2CLH. The term 'dopexamine dihydrochloride' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule dopexamine dihydrochloride under HS 29222900.

SMILES: C1CCC(CC1)CCNCCCCCCNCCC2CCC(C(C2)O)O.CL.CL.

UNSPSC 51392414 Dopexamine dihydrochloride is a Commodity code that encompasses pharmaceutical products for emergency and therapeutic use, though state and local procurement activity under this specific code is sparse. Recent opportunities tagged to this code show minimal alignment with its nominal pharmaceutical scope—the Seminole County solicitation for naloxone and drug deactivation systems, while health-related, represents opioid-overdose emergency supplies rather than dopexamine itself, and the Texas HHS Commission RFI concerns direct-to-manufacturer prescription fulfillment strategy rather than specific pharmaceutical procurement. State and local governments buying under this code do so primarily through county health departments and state health agencies for community health and emergency-response initiatives, though the opportunities present suggest broader pharmaceutical procurement and systems contracting may be tagged more strategically under different commodity codes.

Geographic activity is confined to Florida and Texas based on recent records. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023 (note: deadline predates posting date in source records). Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs without a formal solicitation phase. The code shows little recent activity overall, suggesting that state and local government procurement of dopexamine and related pharmaceutical products either concentrates under alternative UNSPSC classifications, routes through group purchasing organizations or cooperative agreements outside formal competitive solicitations, or remains minimal relative to broader pharmaceutical and health-supply spending.